From CNBC:

The demand for weight loss drugs has surged, but supply has not been able to keep up with it, leading to shortages of the popular injectable treatments. The leading drugmakers, Novo Nordisk and Eli Lilly, are working to address the supply issues while revealing the significant potential of the weight loss drug market. Analysts expect the market to be worth $100 billion by 2030.

Novo Nordisk and Eli Lilly shared updates on positive supply developments and ambitious investments. After facing intermittent shortages, they are working to reassure both investors and patients of their ability to meet the growing demand for their weight loss and diabetes drugs. Other companies are also joining the race to capitalize on the success of these treatments.

Eli Lilly has achieved its goal of doubling production capacity for their incretin drugs and is focused on further expanding production this year. Novo Nordisk and its parent company have revealed multibillion-dollar deals to increase supply, with the aim of gradually increasing manufacturing capacity in the coming years.

Both Novo Nordisk and Eli Lilly have made significant investments to build new production facilities that will help increase supply over the next few years. These efforts aim to address shortages and meet the demands of the weight loss and diabetes drug market as it continues to grow exponentially.

Supply constraints may be alleviated through alternative forms of weight loss drugs. Eli Lilly is planning to launch alternative delivery devices for their popular drugs outside the U.S. to expand production. They are also developing an oral drug that shows promising weight loss results, and analysts believe that such oral forms of weight loss and diabetes drugs will be key to meeting future demands.



Read more: Novo Nordisk, Eli Lilly are tackling supply issues